Log in
Enquire now
‌

Giner, Inc. SBIR Phase I Award, July 2022

A SBIR Phase I contract was awarded to Giner, Inc. in July, 2022 for $124,188.0 USD from the NASA.

OverviewStructured DataIssuesContributors

Contents

sbir.gov/node/2275519
Is a
SBIR/STTR Awards
SBIR/STTR Awards

SBIR/STTR Award attributes

SBIR/STTR Award Recipient
Giner, Inc.
Giner, Inc.
0
Government Agency
NASA
NASA
0
Award Type
SBIR0
Contract Number (US Government)
80NSSC22PB0300
Award Phase
Phase I0
Award Amount (USD)
124,1880
Date Awarded
July 20, 2022
0
End Date
January 25, 2023
0
Abstract

One of NASArsquo;s goals is to determine if past or present life exists outside of Earth. Ocean worlds, bodies that contain liquid oceans, contain many of the key ingredients thought to be necessary for life. Ocean worlds such as Jupiterrsquo;s moon Europa and Saturnrsquo;s moons Titan and Enceladus, are all ocean worlds that are considered prospects for harboring life. NASA is currently funding efforts to develop technologies capable of detecting molecular signatures of life. Giner proposes to assist in these efforts with the invention of a life detection instrument called the Biosignature Life Chip. This instrument utilizes an antibody microarray with antibodies specific to conserved molecular markers that are widely represented in life on Earth. This approach is compatible with NASArsquo;s definition of life, which seeks organisms capable of evolution. Such organisms will likely have similar molecular features including proteins encoded by DNA and cell membranes which encapsulate organelles. Although similar microarray life detection instruments have been proposed, Ginerrsquo;s Biosignature Detection Chip is unique in that it utilizes surface plasmon resonance (SPR) for detection rather than fluorescent detection with labeled secondary antibodies. This allows for a simplified instrument which carriers fewer reagents and buffers and utilizes fewer steps than other similar devices. Ginerrsquo;s Phase I efforts will be directed toward achieving TLR3 by developing an SPR assay capable of selective and specific detection of target antigens. With the completion of Phase I, we will report on the performance of the antibody microarray including sensitivity, specificity, and selectivity for each antibody in the array. Phase II efforts will expand the number of evaluated antibodies and will include the development of a prototype SPR device.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like Giner, Inc. SBIR Phase I Award, July 2022

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.